{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T13:32:34Z","timestamp":1789997554673,"version":"4.0.1"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>This study aimed to evaluate the effectiveness and safety of Allisartan Isoproxil in the management of hypertension.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A comprehensive search was conducted across both English and Chinese databases, including the Cochrane Library, Embase, PubMed, Web of Science, Chinese Journal Full Text Database (CNKI), Wanfang Digital Periodical Full Text Database, and VIP Chinese Periodical Database (VIP), up to March 24, 2024. Randomized controlled trials (RCTs) investigating alisartan axetil for hypertension management were selected. Literature quality was assessed, and data were extracted for meta-analysis using Stata 15.1 software. The quality of evidence for outcome indicators was evaluated using the GRADE system level.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Six RCTs involving 767 participants were included. Meta-analysis revealed that, compared to placebo, the Allisartan Isoproxil group exhibited a significant reduction in systolic blood pressure (SBP) [WMD\u2009=\u2009\u22128.08, 95% CI (\u221211.81, 4.10), <jats:italic>p\u2009<\/jats:italic>=\u20090.000] and brachial-ankle pulse wave velocity (baPWV) [SMD\u2009=\u2009\u22120.69, 95% CI (\u22121.17, 0.20), <jats:italic>p<\/jats:italic>\u2009=\u20090.006]. However, the reduction in diastolic blood pressure (DBP) was not statistically significant [WMD\u2009=\u2009\u22125.48, 95% CI (\u221211.07, 0.10), <jats:italic>p<\/jats:italic>\u2009=\u20090.054]. Additionally, compared to calcium channel blockers (CCB) and angiotensin II receptor blockers (ARB), Allisartan Isoproxil did not significantly affect SBP [WMD\u2009=\u20090.20, 95% CI (\u22123.71, 4.10), <jats:italic>p<\/jats:italic>\u2009=\u20090.921] or DBP [WMD\u2009=\u20090.16, 95% CI (\u22122.11, 2.43), <jats:italic>p<\/jats:italic>\u2009=\u20090.891]. Allisartan Isoproxil demonstrated superior effects in increasing nitric oxide (NO) levels and decreasing endothelin (ET) levels compared to control groups [WMD\u2009=\u20099.56, 95% CI (6.42, 12.71), <jats:italic>p\u2009<\/jats:italic>=\u20090.000], [WMD\u2009=\u2009\u22127.42, 95% CI (\u221211.13, \u22123.71), <jats:italic>p<\/jats:italic>\u2009=\u20090.000], and showed a higher effective control rate of blood pressure [RR\u2009=\u20091.26, 95% CI (1.13, 1.41), <jats:italic>p<\/jats:italic>\u2009=\u20090.000]. Subgroup analysis did not reveal significant differences. Regarding safety, there were no statistically significant differences in adverse events between the Allisartan Isoproxil group and the control groups [RR\u2009=\u20090.99, 95% CI (0.74, 1.32), <jats:italic>p<\/jats:italic>\u2009=\u20090.928], and no fatal adverse events were reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Allisartan Isoproxil is effective in reducing SBP and baPWV, increasing NO, decreasing ET, and achieving a higher control rate of blood pressure in patients with essential hypertension. These benefits are achieved with minimal adverse reactions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p><jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42023467869<\/jats:ext-link>, identifier PROSPERO CRD42023467869.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2024.1355014","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T19:26:18Z","timestamp":1718133978000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety evaluation of Allisartan Isoproxil in patients with hypertension: a meta-analysis"],"prefix":"10.3389","volume":"11","author":[{"given":"Fengfeng","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa2206916","article-title":"Global effect of modifiable risk factors on cardiovascular disease and mortality","volume":"389","author":"Magnussen","year":"2023","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/hjh.0000000000003363","article-title":"Blood pressure variability: methodological aspects, clinical relevance and practical indications for management\u2014a European society of hypertension position paper","volume":"41","author":"Parati","year":"2023","journal-title":"J Hypertens"},{"key":"B3","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/cvr\/cvac130","article-title":"Addressing global disparities in blood pressure control: perspectives of the international society of hypertension","volume":"119","author":"Schutte","year":"2023","journal-title":"Cardiovasc Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41569-022-00829-z","article-title":"Hypertension in China: epidemiology and treatment initiatives","volume":"20","author":"Wang","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/eurjpc\/zwac203","article-title":"New perspectives for hypertension management: progress in methodological and technological developments","volume":"30","author":"Parati","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e1363","DOI":"10.1016\/s2214-109x(23)00280-2","article-title":"Diagnostic testing for hypertension, diabetes, and hypercholesterolaemia in low-income and middle-income countries: a cross-sectional study of data for 994\u2008185 individuals from 57 nationally representative surveys","volume":"11","author":"Ochmann","year":"2023","journal-title":"Lancet Glob Health"},{"key":"B7","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/s41371-021-00513-8","article-title":"Disparities in absolute cardiovascular risk, metabolic syndrome, hypertension, and other risk factors by income within racial\/ethnic groups among middle-aged and older US people","volume":"37","author":"Kibria","year":"2023","journal-title":"J Hum Hypertens"},{"key":"B8","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1093\/ajh\/hpab021","article-title":"Cardiovascular risk assessment in hypertensive patients","volume":"34","author":"Wang","year":"2021","journal-title":"Am J Hypertens"},{"key":"B9","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1161\/hypertensionaha.122.20178","article-title":"Association of home and ambulatory blood pressure with cardiovascular prognosis in practice hypertensive outpatients","volume":"80","author":"Narita","year":"2023","journal-title":"Hypertension"},{"key":"B10","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s40292-023-00568-3","article-title":"Impact of 2021 ESC guidelines for cardiovascular disease prevention on hypertensive patients risk: secondary analysis of save your heart study","volume":"30","author":"Del Pinto","year":"2023","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1161\/hypertensionaha.122.20810","article-title":"Improved persistence to medication, decreased cardiovascular events and reduced all-cause mortality in hypertensive patients with use of single-pill combinations: results from the START-study","volume":"80","author":"Schmieder","year":"2023","journal-title":"Hypertension"},{"key":"B12","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1001\/jama.2023.2307","article-title":"Cardiovascular risk factor prevalence, treatment, and control in US adults aged 20 to 44 years, 2009 to march 2020","volume":"329","author":"Aggarwal","year":"2023","journal-title":"Jama"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1093\/eurheartj\/ehac395","article-title":"Hypertension management in patients with cardiovascular comorbidities","volume":"44","author":"Lauder","year":"2023","journal-title":"Eur Heart J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1038\/s41440-023-01397-6","article-title":"Home blood pressure-centered approach\u2014from digital health to medical practice: HOPE Asia network consensus statement 2023","volume":"46","author":"Kario","year":"2023","journal-title":"Hypertens Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/s41440-022-01137-2","article-title":"Status of ambulatory blood pressure monitoring and home blood pressure monitoring for the diagnosis and management of hypertension in the US: an up-to-date review","volume":"46","author":"Cepeda","year":"2023","journal-title":"Hypertens Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/jch.14653","article-title":"Comprehensive effects of lifestyle reform, adherence, and related factors on hypertension control: a review","volume":"25","author":"Ojangba","year":"2023","journal-title":"J Clin Hypertens"},{"key":"B17","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41371-023-00801-5","article-title":"Hypertension: sex-related differences in drug treatment, prevalence and blood pressure control in primary care","volume":"37","author":"Bager","year":"2023","journal-title":"J Hum Hypertens"},{"key":"B18","doi-asserted-by":"publisher","first-page":"115703","DOI":"10.1016\/j.jep.2022.115703","article-title":"Integrated Chinese herbal medicine with Western Medicine versus Western Medicine in the effectiveness of primary hypertension treatment: a systematic review and meta-analysis of randomized controlled trials","volume":"300","author":"Mohammed","year":"2023","journal-title":"J Ethnopharmacol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"16399","DOI":"10.20452\/pamw.16399","article-title":"Multiple drug intolerance in patients with arterial hypertension: prevalence and determining factors","volume":"133","author":"Polaczyk","year":"2023","journal-title":"Pol Arch Intern Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e832","DOI":"10.3399\/bjgp.2023.0153","article-title":"Impact of ACEIs and ARBs-related adverse drug reaction on patients\u2019 clinical outcomes: a cohort study in UK primary care","volume":"73","author":"Insani","year":"2023","journal-title":"Br J Gen Pract"},{"key":"B21","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s11906-023-01248-2","article-title":"ACE-inhibitors in hypertension: a historical perspective and current insights","volume":"25","author":"Cutrell","year":"2023","journal-title":"Curr Hypertens Rep"},{"key":"B22","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s40256-023-00605-5","article-title":"The pivotal role of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in hypertension management and cardiovascular and renal protection: a critical appraisal and comparison of international guidelines","volume":"23","author":"Alcocer","year":"2023","journal-title":"Am J Cardiovasc Drugs"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e1056","DOI":"10.1002\/hsr2.1056","article-title":"Long-term mortality and cardiovascular events of seven angiotensin receptor blockers in hypertensive patients: analysis of a national real-world database: a retrospective cohort study","volume":"6","author":"Lee","year":"2023","journal-title":"Health Sci Rep"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e54311","DOI":"10.7759\/cureus.54311","article-title":"A comparative study of the safety and efficacy between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the management of hypertension: a systematic review","volume":"16","author":"Peresuodei","year":"2024","journal-title":"Cureus"},{"key":"B25","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/jch.14757","article-title":"Management of nocturnal hypertension: an expert consensus document from Chinese hypertension league","volume":"26","author":"Liu","year":"2024","journal-title":"J Clin Hypertens"},{"key":"B26","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3892\/etm.2024.12508","article-title":"Transcriptome and proteome analyses reveal that upregulation of GSTM2 by allisartan improves cardiac remodeling and dysfunction in hypertensive rats","volume":"27","author":"Wu","year":"2024","journal-title":"Exp Ther Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/ajh\/hpad055","article-title":"Efficacy of allisartan isoproxil in the treatment of mild-to-moderate essential hypertension","volume":"36","author":"Wang","year":"2023","journal-title":"Am J Hypertens"},{"key":"B28","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/jch.14773","article-title":"Effects of allisartan-isoproxil-based combination antihypertensive regimen in hypertensive patients with microalbuminuria or hyperuricemia","volume":"26","author":"Sun","year":"2024","journal-title":"J Clin Hypertens"},{"key":"B29","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br Med J"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/hjh.0000000000003480","article-title":"2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European society of hypertension: endorsed by the international society of hypertension (ISH) and the European renal association (ERA)","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1111\/jch.14738","article-title":"Efficacy and safety of community-based moxibustion for primary hypertension: a randomized controlled trial with patient preference arms","volume":"25","author":"Zhou","year":"2023","journal-title":"J Clin Hypertens"},{"key":"B32","doi-asserted-by":"publisher","first-page":"105913","DOI":"10.1016\/j.cct.2019.105913","article-title":"Strategy of blood pressure intervention in the elderly hypertensive patients (STEP): rational, design, and baseline characteristics for the main trial","volume":"89","author":"Zhang","year":"2020","journal-title":"Contemp Clin Trials"},{"key":"B33","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jclinepi.2023.03.003","article-title":"GRADE Guidance 36: updates to GRADE\u2019s approach to addressing inconsistency","volume":"158","author":"Guyatt","year":"2023","journal-title":"J Clin Epidemiol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.1007\/s12325-020-01413-y","article-title":"Allisartan isoproxil improves endothelial function and vascular damage in patients with essential hypertension: a single-center, open-label, randomized controlled trial","volume":"37","author":"Zhang","year":"2020","journal-title":"Adv Ther"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e14907","DOI":"10.1097\/md.0000000000014907","article-title":"Effects of allisartan isoproxil on blood pressure and target organ injury in patients with mild to moderate essential hypertension","volume":"98","author":"Zhang","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e0117560","DOI":"10.1371\/journal.pone.0117560","article-title":"A randomized, double blind, placebo-controlled, multicenter phase II trial of Allisartan Isoproxil in essential hypertensive population at low-medium risk","volume":"10","author":"Li","year":"2015","journal-title":"PLoS One"},{"key":"B37","doi-asserted-by":"publisher","first-page":"728","DOI":"10.13699\/j.cnki.1001-6821.2013.10.006","article-title":"Efficacy and safety of alisatanate in the treatment of mild to moderate essential hypertension","volume":"29","author":"Jing","year":"2013","journal-title":"Chin J Clin Pharmacol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3969\/j.issn.1002-266X.2015.34.017","article-title":"The efficacy of alisatan ester in the treatment of hypertension combined with stable angina pectoris","volume":"55","author":"Zhao","year":"2015","journal-title":"Shandong Med J"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.13699\/j.cnki.1001-6821.2021.19.004","article-title":"Clinical study of alisatan ester tablets versus irbesartan tablets in the treatment of patients with hypertension combined with coronary heart disease","volume":"37","author":"Xie","year":"2021","journal-title":"Chin J Clin Pharmacol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1097\/hjh.0000000000002843","article-title":"2021 European society of hypertension practice guidelines for office and out-of-office blood pressure measurement","volume":"39","author":"Stergiou","year":"2021","journal-title":"J Hypertens"},{"key":"B41","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3238\/arztebl.m2021.0158","article-title":"Monitoring of treatment for arterial hypertension\u2013the role of office, home, and 24\u2005h ambulatory blood pressure measurement","volume":"118","author":"Mengden","year":"2021","journal-title":"Dtsch Arztebl Int"},{"key":"B42","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/aps.2009.11","article-title":"Effects of allisartan, a new AT(1) receptor blocker, on blood pressure and end-organ damage in hypertensive animals","volume":"30","author":"Wu","year":"2009","journal-title":"Acta Pharmacol Sin"},{"key":"B43","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1097\/hjh.0000000000003636","article-title":"Standardized treatment protocols for hypertension: global availability, characteristics, and alignment with the hypertension guideline recommendations","volume":"42","author":"Satheesh","year":"2024","journal-title":"J Hypertens"},{"key":"B44","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41392-023-01430-7","article-title":"Signaling pathways in vascular function and hypertension: molecular mechanisms and therapeutic interventions","volume":"8","author":"Ma","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1007\/s00467-022-05802-z","article-title":"Endothelial dysfunction as a factor leading to arterial hypertension","volume":"38","author":"Dro\u017cd\u017c","year":"2023","journal-title":"Pediatr Nephrol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1098725","DOI":"10.3389\/fimmu.2022.1098725","article-title":"Role of inflammation, immunity, and oxidative stress in hypertension: new insights and potential therapeutic targets","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1097\/hjh.0000000000003400","article-title":"Arterial stiffness and blood pressure in treated hypertension: a longitudinal study","volume":"41","author":"Wu","year":"2023","journal-title":"J Hypertens"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1038\/s41440-023-01313-y","article-title":"Brachial-ankle pulse wave velocity is a stronger predictor than blood pressure for atherosclerotic cardiovascular diseases and all-cause mortality: a cohort study","volume":"46","author":"Yang","year":"2023","journal-title":"Hypertens Res"},{"key":"B49","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.niox.2022.12.002","article-title":"Heterogenous improvements in endothelial function by sub-blood pressure lowering doses of ARBs result in major anti-aortic root remodeling effects","volume":"131","author":"Tehrani","year":"2023","journal-title":"Nitric Oxide"},{"key":"B50","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s41401-021-00684-7","article-title":"Allisartan isoproxil reduces mortality of stroke-prone rats and protects against cerebrovascular, cardiac, and aortic damage","volume":"42","author":"Ling","year":"2021","journal-title":"Acta Pharmacol Sin"},{"key":"B51","doi-asserted-by":"publisher","first-page":"6702","DOI":"10.3390\/ijms22136702","article-title":"Renin-Angiotensin system in pathogenesis of atherosclerosis and treatment of CVD","volume":"22","author":"Poznyak","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B52","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3892\/mmr.2021.11854","article-title":"Allisartan isoproxil attenuates oxidative stress and inflammation through the SIRT1\/Nrf2\/NF\u03baB signalling pathway in diabetic cardiomyopathy rats","volume":"23","author":"Jin","year":"2021","journal-title":"Mol Med Rep"},{"key":"B53","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/bcpt.13321","article-title":"Modelling gastric emptying: a pharmacokinetic model simultaneously describing distribution of losartan and its active metabolite EXP-3174","volume":"126","author":"Karatza","year":"2020","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/cpdd.1327","article-title":"Comparison of pharmacokinetics and bioavailability of fixed-dose combination tablet and monotherapy combination of allisartan isoproxil and indapamide sustained-release in healthy Chinese volunteers","volume":"13","author":"Fan","year":"2024","journal-title":"Clin Pharmacol Drug Dev"},{"key":"B55","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1124\/dmd.118.085092","article-title":"Carboxylesterase 2 and intestine transporters contribute to the low bioavailability of allisartan, a prodrug of Exp3174 for hypertension treatment in humans","volume":"47","author":"Li","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"B56","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/cpdd.995","article-title":"Pharmacokinetics and safety of a single dose and multiple doses of allisartan isoproxil, an angiotensin II receptor blocker, in healthy Chinese people","volume":"11","author":"Yi","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"key":"B57","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/cpdd.1327","article-title":"Comparison of pharmacokinetics and bioavailability of fixed-dose combination tablet and monotherapy combination of allisartan isoproxil and indapamide sustained-release in healthy Chinese Volunteers","volume":"13","author":"Fan","year":"2023","journal-title":"Clin Pharmacol Drug Dev"},{"key":"B58","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jcmg.2019.03.028","article-title":"Prediction of stroke risk by detection of hemorrhage in carotid plaques: meta-analysis of individual patient data","volume":"13","author":"Schindler","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.2337\/dc16-0346","article-title":"Do Mobile phone applications improve glycemic control (HbA1c) in the self-management of diabetes? A systematic review, meta-analysis, and GRADE of 14 randomized trials","volume":"39","author":"Hou","year":"2016","journal-title":"Diabetes Care"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1355014\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T19:26:32Z","timestamp":1718133992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1355014\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,6]]},"references-count":59,"alternative-id":["10.3389\/fcvm.2024.1355014"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2024.1355014","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,6]]},"article-number":"1355014"}}